Computer Methods for Predicting Drug Metabolism

Computer Applications in Pharmaceutical Research and Development

Volumn , Issue , 2006, Pages 443-468

  Ekins, Sean ^a  

^a NONE   (United States)

Author keywords

Computer methods in predicting drug metabolism; Metabolism prediction applications; Statistical, pharmacophore, and homology models

Indexed keywords

EID: 33845659053     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/0470037237.ch18     Document Type: Chapter

References (152)

1. Austel V, Kutter E. Absorption, distribution, and metabolism of drugs. In:Topliss, EJ, editor, Quantitative structure-activity relationships of drugs. New York: Academic Press, 1983. p. 437-96.
2. Nelson DR. Introductory remarks on human CYPs. Drug Metab Rev 2002;34:1-5.
3. Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, et al. Drugdrug interactions for UDP-glucuronosyltransferase substrates: a pharmacoki netic explanation for typically observed low exposure (auci/auc) ratios. Drug Metab Dispos 2004;32:1201-8.
4. Ekins S. Predicting undesirable drug interactions with promiscuous proteins in silico. Drug Discov Today 2004;9:276-85.
5. Lewis DFV. Cytochromes P450. Bristol, UK: Taylor & Francis, 1996.
6. Kesuru GM, Molnar L. METAPRINT: a metabolic fingerprint. Application to cassette design for high-throughput ADME screening. J Chem Inf Comput Sci 2002;42:437-44.
7. Hansch C, Deutsch EW, Smith RN. The use of substituent constants and regression analysis in the study of enzymatic reaction mechanisms. J Am Chem Soc 1965;87:2738-42.
8. Hansch C, Steward AR, Iwasa J. The use of substituent constants in the correlation of demethylation rates. J Med Chem 1965;8:868-70.
9. Hansch C. Quantitative relationships between lipophilic character and drug metabolism. Drug Metab Rev 1972;1:1-14.
10. Hansch C. The QSAR paradigm in the design of less toxic molecules. Drug Metab Rev 1984;15:1279-94.
11. Hansch C, Lien EJ, Helmer F. Structure-activity correlations in the metabolism of drugs. Arch Biochem Biophys 1968;128:319-30.
12. Hansch C, Zhang L. Quantitative structure-activity relationships of cytochrome P-450. Drug Metab Rev 1993;25:1-48.
13. Lewis DFV. Quantitative structure activity relationships in substrates, inducers, and inhibitors of cytochrome P4501 (CYP1). Drug Metab Rev 1997;29:589-650.
14. Lewis DFV. On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics. Biochem Pharmacol 2000;60:293-306.
15. Lewis DFV. Structural characteristics of human P450s involved in drug metabolism:QSARs and lipophilicity profiles. Toxicology 2000;144:197-203.
16. Lewis DFV, Eddershaw PJ, Dickins M, Tarbit MH, Goldfarb PS. Structural determinants of cytochrome P450 substrate specificity, binding affinity and catalytic rate. Chem Bio Interact 1998;115:175-99.
17. Lewis DFV, Eddershaw PJ, Dickins M, Tarbit MH, Goldfarb PS. Erratum to "Structural determinants of cytochrome P450 substrate specificity, binding affinity and catalytic rate". Chem Biol Interact 1999;117:187.
18. Lewis DF, Jacobs MN, Dickins M. Compound lipophilicity for substrate binding to human P450s in drug metabolism. Drug Discov Today 2004;9:530-7.
19. Ekins S, Swaan PW. Computational models for enzymes, transporters, channels and receptors relevant to ADME/TOX. Rev Comp Chem 2004;20:333-415.
20. Fuhr U, Strobl G, Manaut F, Anders E-M, Sorgel F, Lopez-de-brinas E, et al. Quinolone antibacterial agents: relationship between structure and in vitro inhibition of human cytochrome P450 isoform CYP1A2. Mol Pharmacol 1993;43:191-9.
21. Jones JP, Korzekwa KR. Predicting the rates and regioselectivity of reactions mediated by the P450 superfamily. New York: Academic Press. 1996.
22. Ekins S, de Groot M, Jones JP. Pharmacophore and three dimensional quantitative structure activity relationship methods for modeling cytochrome P450 active sites. Drug Metab Dispos 2001;29:936-44.
23. Ekins S, VandenBranden M, Ring BJ, Wrighton SA. Examination of purported probes of human CYP2B6. Pharmacogenetics 1997;7:165-79.
24. Ekins S, VandenBranden M, Ring BJ, Gillespie JS, Yang TJ, Gelboin HV, et al. Further characterization of the expression and catalytic activity of human CYP2B6. J Pharmacol Exp Ther 1998;286:1253-9.
25. Ekins S, Bravi G, Ring BJ, Gillespie TA, Gillespie JS, VandenBranden M, et al. Three dimensional-quantitative structure activity relationship (3D-QSAR) analyses of substrates for CYP2B6. J Pharmacol Exp Ther 1999;288:21-9.
26. Ekins S, Bravi G, Wikel JH, Wrighton SA. Three dimensional quantitative structure activity relationship (3D-QSAR) analysis of CYP3A4 substrates. J Pharmacol Exp Ther 1999;291:424-33.
27. Ekins S, Bravi G, Binkley S, Gillespie JS, Ring BJ, Wikel JH, et al. Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors. Pharmacogenetics 1999;9:477-89.
28. Ekins S, Bravi G, Binkley S, Gillespie JS, Ring BJ, Wikel JH, et al. Three and four dimensional-quantitative structure activity relationship analyses of CYP3A4 inhibitors. J Pharmacol Exp Ther 1999;290:429-38.
29. Ekins S, Bravi G, Binkley S, Gillespie JS, Ring BJ, Wikel JH, et al. Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors. Drug Metab Dispos 2000;28:994-1002.
30. Snyder R, Sangar R, Wang J, Ekins S. Three dimensional quantitative structure activity relationship for CYP2D6 substrates. Quant Struct Act Relationship 2002;21:357-68.
31. Ekins S, Stresser DM, Williams JA. In vitro and pharmacophore insights into CYP3A enzymes. Trends Pharmacol Sci 2003;24:191-6.
32. Ekins S, Wrighton SA. Application of in silico approaches to predicting drugdrug interactions: a commentary. J Pharm Tox Methods 2001;44:1-5.
33. Asikainen A, Tarhanen J, Poso A, Pasanen M, Alhava E, Juvonen RO. Predictive value of comparative molecular field analysis modelling of naphthalene inhibition of human CYP2A6 and mouse CYP2A5 enzymes. Toxicol In Vitro 2003;17:449-55.
34. Wrighton SA, Schuetz EG, Thummel KE, Shen DD, Korzekwa KR, Watkins PB. The human CYP3A subfamily: practical considerations. Drug Metab Rev 2000;32:339-61.
35. Ekins S, Wrighton SA. The role of CYP2B6 in human xenobiotic metabolism. Drug Metab Rev 1999;31:719-54.
36. Ekins S, Berbaum J, Harrison RK. Generation and validation of rapid computational filters for CYP2D6 and CYP3A4. Drug Metab Dispos 2003;31:1077-80.
37. Egnell AC, Houston JB, Boyer CS. Predictive models of CYP3A4 heteroactivation:in vitro-in vivo scaling and pharmacophore modelling. J Pharmacol Exp Ther 2005;312:926-37.
38. Egnell AC, Eriksson C, Albertson N, Houston B, Boyer S. Generation and evaluation of a CYP2C9 heteroactivation pharmacophore. J Pharmacol Exp Ther 2003;307:878-87.
39. Cosme J, Johnson EF. Engineering microsomal cytochrome P450 2C5 to be a soluble, monomeric enzyme. Mutations that alter aggregation, phospholipid dependence of catalysis, and membrane binding. J Biol Chem 2000;275:2545-53.
40. Williams PA, Cosme J, Ward A, Angove HC, Matak Vinkovic D, Jhoti H. Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature 2003;424:464-8.
41. Williams PA, Cosme J, Sridhar V, Johnson EF, McRee DE. Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. Mol Cell 2000;5:121-31.
42. Williams PA, Cosme J, Vinkovic DM, Ward A, Angove HC, Day PJ, et al. Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone. Science 2004;305:683-6.
43. Yano JK, Wester MR, Schoch GA, Griffin KJ, Stout CD, Johnson EF. The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-Å resolution. J Biol Chem 2004;279:38091-4.
44. Koymans LMH, Vermeulen NPE, Baarslag A, Donne-Op den Kelder GM. A preliminary 3D model for cytochrome P450 2D6 constructed by homology model building. J Comput-Aided Mol Des 1993;7:281-9.
45. Modi S, Paine MJ, Sutcliffe MJ, Lian L-Y, Primrose WU, Wolf CR, et al. A model for human cytochrome P4502D6 based on homology modeling and NMR studies of substrate binding. Biochemistry 1996;35:4540-50.
46. Lewis DFV, Lake BG, Dickins M, Eddershaw PJ, Tarbit MH, Goldfarb PS. Molecular modelling of CYP2B6, the human CYP2B isoform, by homology with the substrate-bound CYP102 crystal structure: evaluation of CYP2B6 substrate characteristics, the cytochrome b5 binding site and comparisons with CYP2B1 and CYP2B4. Xenobiotica 1999;29:361-93.
47. Szklarz GD, Halpert JR. Use of homology modeling in conjunction with sitedirected mutagenesis for analysis of structure-function relationships of mammalian cytochromes P450. Life Sci 1997;61:2507-20.
48. Szklarz GD, Halpert JR. Molecular modeling of cytochrome P4503A4. J Comput-Aided Mol Des 1997;11:265-72.
49. Szklarz GD, Graham SE, Paulsen MD. Molecular modeling of mammalian cytochromes P450: application to study enzyme function. Vitamins Hormones 2000;58:53-87.
50. Lewis DFV, Eddershaw PJ, Goldfarb PS, Tarbit MH. Molecular modelling of cytochrome P4502D6 (CYP2D6) based on an alignment with CYP102:structural studies on specific CYP2D6 substrate metabolism. Xenobiotica 1997;27:319-40.
51. Lewis DFV, Eddershaw PJ, Goldfarb PS, Tarbit MH. Molecular modelling of CYP3A4 from an alignment with CYP102: identification of key interactions between putative active site residues and CYP3A- specific chemicals. Xenobiotica 1996;10:1067-86.
52. Lewis DFV, Dickins M, Weaver RJ, Eddershaw PJ, Goldfarb PS, Tarbit MH. Molecular modelling of human CYP2C subfamily enzymes CYP2C9 and CYP2C19: rationalization of substrate specificity and site-directed mutagenesis experiments in the CYP2C subfamily. Xenobiotica 1998;28:235-68.
53. Lewis DFV. Three-dimensional models of human and other mammalian microsomal P450s constructed from an alignment with P450102 (P450bm3). Xenobiotica 1995;25:333-66.
54. Wiseman H, Lewis DFV. The metabolism of tamoxifen by human cytochromes P450 is rationalized by molecular modelling of the enzyme substrate interac- tions: potential importance to its proposed anti-carcinogenic/carcinogenic actions. Carcinogenesis 1996;17:1357-60.
55. Afzelius L, Zamora I, Ridderstrom M, Andersson TB, Karlen A, Masimirembwa CM. Competitive CYP2C9 inhibitors: enzyme inhibition studies, protein homology modeling, and three dimensional quantitative structure activity relationship analysis. Mol Pharmacol 2001;59:909-19.
56. Barhelt C, Schmid RD, Pleiss J. Regioselectivity of CYP2B6: homology modeling, molecular dynamics simulation, docking. J Mol Model 2002;8:327-35.
57. Wang Q, Halpert JR. Combined three-dimensional quantitative structureactivity relationship analysis of cytochrome P450 2B6 substrates and protein homology modeling. Drug Metab Dispos 2002;30:86-95.
58. de Groot MJ, Alex AA, Jones BC. Development of a combined protein and pharmacophore model for cytochrome P450 2C9. J Med Chem 2002;45:1983-93.
59. de Groot MJ, Ackland MJ, Horne VA, Alex AA, Jones BC. Novel approach to predicting P450-mediated drug metabolism: development of a combined protein and pharmacophore model for CYP2D6. J Med Chem 1999;42:1515-24.
60. de Groot MJ, Ackland MJ, Horne VA, Alex AA, Jones BC. A novel approach to predicting P450 mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6. J Med Chem 1999;42:4062-70.
61. Tukey RH, Strassburg CP. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 2000;40:581-616.
62. Ethell BT, Ekins S, Wang J, Burchell B. Quantitative structure activity relationships for the glucuronidation of simple phenols by expressed human UGT1A6 and UGT1A9. Drug Metab Dispos 2002;30:734-8.
63. Smith PA, Sorich M, McKinnon R, Miners JO. QSAR and pharmacophore modelling approaches for the prediction of UDP-glucuronosyltransferase substrate selectivity and binding. Pharmacologist 2002;44 supplement.
64. Smith PA, Sorich MJ, McKinnon RA, Miners JO. Pharmacophore and quantitative structure-activity relationship modeling: complementary approaches for the rationalization and prediction of UDP-glucuronosyltransferase 1A4 substrate selectivity. J Med Chem 2003;46:1617-26.
65. Sorich M, Smith PA, McKinnon RA, Miners JO. Pharmacophore and quantitative structure activity relationship modelling of UDP-glucuronosyltransferase 1A1 (UGT1A1) substrates. Pharmacogenetics 2002;12:635-45.
66. Smith PA, Sorich MJ, McKinnon RA, Miners JO. In silico insights:chemical and structural characteristics associated with uridine diphosphateglucuronosyltransferase substrate selectivity. Clin Exp Pharmacol Physiol 2003;30:836-40.
67. Sorich MJ, Miners JO, McKinnon RA, Smith PA. Multiple pharmacophores for the investigation of human UDP-glucuronosyltransferase isoform substrate selectivity. Mol Pharmacol 2004;65:301-8.
68. Sorich MJ, McKinnon RA, Miners JO, Winkler DA, Smith PA. Rapid prediction of chemical metabolism by human UDP-glucuronosyltransferase isoforms using quantum chemical descriptors derived with the electronegativity equalization method. J Med Chem 2004;47:5311-7.
69. Dajani R, Cleasby A, Neu M, Wonacott AJ, Jhoti H, Hood AM, et al. X-ray crystal structure of human dopamine sulfotransferase, SULT1A3. J Biol Chem 1999;53:37862-8.
70. Gamage NU, Duggleby RG, Barnett AC, Tresillian M, Latham CF, Liyou NE, et al. Structure of a human carcinogen-converting enzyme, SULT1A1. J Biol Chem 2003;278:7655-62.
71. Rusinko A, 3rd, Farmen MW, Lambert CG, Brown PL, Young SS. Analysis of a large structure/biological activity data set using recursive partitioning. J Chem Inf Comput Sci 1999;39:1017-26.
72. Ekins S. In silico approaches to predicting metabolism, toxicology and beyond. Biochem Soc Trans 2003;31:611-4.
73. Shen M, Xiao Y, Golbraikh A, Gombar VK, Tropsha A. Development and validation of k-nearest neighbour QSPR models of metabolic stability of drug candidates. J Med Chem 2003;46:3013-20.
74. Kohonen T. Self-organisation and associative memory. Berlin: Springer-Verlag, 1989.
75. Balakin KV, Ekins S, Bugrim A, Ivanenkov YA, Korolev D, Nikolsky Y, et al. Kohonen maps for prediction of binding to human cytochrome P450 3A4. Drug Metab Dispos 2004;32:1183-9.
76. Mitchell M. An introduction to genetic algorithms. Cambridge, MA: MIT Press, 1996.
77. Balakin KV, Ekins S, Bugrim A, Ivanenkov YA, Korolev D, Nikolsky Y, et al. Quantitative structure-metabolism relationship modeling of the metabolic N-dealkylation rates. Drug Metab Dispos 2004;32:1111-20.
78. Korolev D, Balakin KV, Nikolsky Y, Kirillov E, Ivanenkov YA, Savchuk NP, et al. Modeling of human cytochrome P450-mediated drug metabolism using unsupervised machine learning approach. J Med Chem 2003;46:3631-43.
79. Bugrim A, Nikolskaya T, Nikolsky Y. Early prediction of drug metabolism and toxicity: systems biology approach and modeling. Drug Discov Today 2004;9:127-35.
80. Berellini G, Cruciani G, Mannhold R. Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists. J Med Chem 2005;48:4389-99.
81. Jones JP, Mysinger M, Korzekwa KR. Computational models for cytochrome P450: a predictive electronic model for aromatic oxidation and hydrogen abstraction. Drug Metab Dispos 2002;30:7-12.
82. Singh SB, Shen LQ, Walker MJ, Sheridan RP. A model for likely sites of CYP3A4- mediated metabolism on drug-like molecules. J Med Chem 2003;46:1330-6.
83. Csanady GA, Laib JG. Metabolic transformation of halogenated and other alkenes- a theoretical approach. Estimation of metabolic reactivities for in vivo conditions. Toxicology 1995;75:217-23.
84. Yin H, Anders MW, Korzekwa KR, Higgins L, Thummel KE, Kharasch ED, et al. Designing safer chemicals: predicting the rates of metabolism of halogenated alkanes. Proc Natl Acad Sci USA 1995;92:11076-80.
85. Korzekwa K, Ewing TJ, Kocher JP, Carlson TJ. Models for cytochrome P450- mediated metabolism. In: Borchardt RT, Kerns EH, Lipinski CA, Thakker DR, Wang B, editors, Pharmaceutical profiling in drug discovery for lead selection. Arlington, VA: AAPS Press, 2004. p. 69-80.
86. Bursi R, de Gooyer ME, Grootenhuis A, Jacobs PL, van der Louw J, Leysen D. (Q)SAR study on the metabolic stability of steroidal androgens. J Mol Graph Modelling 2001;19:552-6.
87. Kliewer SA, Moore JT, Wade L, Staudinger JL, Watson MA, Jones SA, et al. An orphan nuclear receptor activated by pregnanes defines a novel steroid signalling pathway. Cell 1998;92:73-82.
88. Nakata K, Yukawa M, Komiyama N, Nakano T, Kaminuma T. A nuclear receptor database that maps pathways to diseases. Genome Infomatics 2002;13:515-6.
89. Schapira M, Raaka BM, Samuels HH, Abagyan R. Rational discovery of novel nuclear hormone receptor antagonists. Proc Natl Acad Sci USA 2000;97:1008-13.
90. Sun LZ, Ji ZL, Chen X, Wang JF, Chen YZ. ADME-AP: a database of ADME associated proteins. Bioinformatics 2002;18:1699-700.
91. Erhardt PW. A human drug metabolism database: potential roles in the quantitative predictions of drug metabolism and metabolism-related drug-drug interactions. Curr Drug Metab 2003;4:411-22.
92. Boyer S, Zamora I. New methods in predictive metabolism. J Comput-Aided Mol Des 2002;16:403-13.
93. Borodina Y, Sadym A, Filimonov D, Blinova V, Dmitriev A, Poroikov V. Predicting biotransformation potential from molecular structure. J Chem Inf Comput Sci 2003;43:1636-46.
94. Borodina Y, Rudik A, Filimonov D, Kharchevnikova N, Dmitriev A, Blinova V, et al. A new statistical approach to predicting aromatic hydroxylation sites. Comparison with model-based approaches. J Chem Inf Comput Sci 2004; 44:1998-2009.
95. Smith RV, Erhardt PW, Leslie SW. Microsomal O-demethylation, N-demethylation and aromatic hydroxylation in the presence of bisulfite and dithiothreitol. Res Commun Chem Path Pharmacol 1975;12:181-4.
96. Darvas F, Dorman G, Papp A. Diversity measures for enhancing ADME admissibility of combinatorial libraries. J Chem Inf Comput Sci 2000;40:314-22.
97. Klopman G, Dimayuga M, Talafous J. META. 1. A program for the evaluation of metabolic transformations of chemicals. J Chem Inf Comput Sci 1994;34:1320-5.
98. Talafous J, Sayre LM, Mieyal JJ, Klopman G. META. 2. A dictionary model of mammalian xenobiotic metabolism. J Chem Inf Comput Sci 1994;34:1326-33.
99. Klopman G, Tu M, Talafous J. META. 3. A genetic algorithm for metabolic transform priorities optimization. J Chem Inf Comput Sci 1997;37:329-34.
100. Langowski J, Long A. Computer systems for the prediction of xenobiotic metabolism. Adv Drug Del Rev 2002;54:407-15.
101. Button WG, Judson PN, Long A, Vessey JD. Using absolute and relative reasoning in the prediction of the potential metabolism of xenobiotics. J Chem Inf Comput Sci 2003;43:1371-7.
102. Hou BK, Ellis LB, Wackett LP. Encoding microbial metabolic logic: predicting biodegradation. J Ind Microbiol Biotechnol 2004;31:261-72.
103. Hou BK, Wackett LP, Ellis LB. Microbial pathway prediction: a functional group approach. J Chem Inf Comput Sci 2003;43:1051-7.
104. Ellis LB, Hou BK, Kang W, Wackett LP. The University of Minnesota Biocatalysis/ Biodegradation Database: post-genomic data mining. Nucleic Acids Res 2003;31:262-5.
105. Mekenyan OG, Dimitrov SD, Pavlov TS, Veith GD. A systematic approach to simulating metabolism in computational toxicology. I. The TIMES heuristic modelling framework. Curr Pharm Des 2004;10:1273-93.
106. Gifford EM, Johnson MA, Smith DA, Tsai CC. Structure-reactivity maps as a tool for visualizing xenobiotic structure reactivity relationships. http://wwwnetsciorg/Science/Special/feature04html 1996.
107. Cook DL, Atkins WM. Enhanced detoxication due to distributive catalysis and toxic thresholds: a kinetic analysis. Biochemistry 1997;36:10802-6.
108. Young SS, Ekins S, Lambert C. So many targets, so many compounds, but so few resources. Curr Drug Discov 2002;December:17-22.
109. Young SS, Gombar VK, Emptage MR, Cariello NF, Lambert C. Mixture deconvolution and analysis of Ames mutagenicity data. Chemo Intell Lab Sys 2002;60:5-11.
110. Li AP. A review of the common properties of drugs with idiosyncratic hepatotoxicity and the "multiple determinant hypothesis" for the manifestation of idiosyncratic drug toxicity. Chem Biol Interact 2002;142:7-23.
111. Williams DP, Park BK. Idiosyncratic toxicity: the role of toxicophores and bioactivation. Drug Discov Today 2003;8:1044-50.
112. Uetrecht J. Screening for the potential of a drug candidate to cause idiosyncratic drug reactions. Drug Discov Today 2003;8:832-7.
113. Ekins S, Nikolsky Y, Nikolskaya T. Techniques: Application of systems biology to absorption, distribution, metabolism, excretion, and toxicity. Trends Pharmacol Sci 2005;26:202-9.
114. Rosipal R, Trejo LJ. Kernel partial least squares regression in reproducing Kernel Hilbert space. J Machine Learning Res 2001;2:97-123.
115. Bennett KP, Embrechts MJ. An optimization perspective on kernel partial least squares regression. In: Suykens JAK, Horvath G, Basu S, Micchelli J, Vandewalle J, editors, Advances in learning theory; methods, models and applications. Amsterdam: IOS Press, 2003. p. 227-50.
116. Anari MR, Baillie TA. Bridging cheminformatic metabolite prediction and tandem mass spectrometry. Drug Discov Today 2005;10:711-7.
117. Anari MR, Sanchez RI, Bakhtiar R, Franklin RB, Baillie TA. Integration of knowledge-based metabolic predictions with liquid chromatography data-dependent tandem mass spectrometry for drug metabolism studies:application to studies on the biotransformation of indinavir. Anal Chem 2004;76:823-32.
118. Ertl P, Rohde B, Selzer P. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J Med Chem 2000;43:3714-7.
119. Willet P. Similarity-based approaches to virtual screening. Biochem Soc Trans 2003;31:603-6.
120. Kirton SB, Baxter CA, Sutcliffe MJ. Comparative modelling of the cytochromes P450. Adv Drug Del Rev 2002;54:385-406.
121. Nedelcheva V, Gut I. P450 in the rat and man: methods of investigation, substrate specificities and relevance to cancer. Xenobiotica 1994;24:1151-75.
122. Leahy D. Drug Discovery information integration: virtual humans for pharmacokinetics. DDT: Biosilico 2004;2:78-84.
123. Kim YM, Ziegler DM. Size limits of thiocarbamides accepted as substrates by human flavin-containing monooxygenase 1. Drug Metab Dispos 2000;28:1003-6.
124. Soffers AEMF, Ploeman JHTM, Moonen MJH, Wobbes T, van Ommen B, Vervoort J, et al. Regioselectivity and quantitative structure-activity relationships for the conjugation of a series of fluoronitrobenzenes by purified glutathione S-transferase enzymes from rat and man. Chem Res Toxicol 1996;9:638-46.
125. Medvedev AE, Veselovsky AV, Shvedov VI, Tikhonova OV, Moskvitina TA, Fedotova OA, et al. Inhibition of monoamine oxidase by pirlindole analogues:3D-QSAR and CoMFA analysis. J Chem Inf Comput Sci 1998;38:1137-44.
126. Miller JR, Edmondson DE. Structure-activity relationships in the oxidation of para-substituted benzylamine analogues by recombinant human liver monoamine oxidase A. Biochemistry 1999;38:13670-83.
127. Ekins S, Waller CL, Swaan PW, Cruciani G, Wrighton SA, Wikel JH. Progress in predicting human ADME parameters in silico. J Pharmacol Toxicol Methods 2000;44:251-72.
128. Reck F, Zhou F, Girardot M, Kern G, Eyermann CJ, Hales NJ, et al. Identification of 4-substituted 1,2,3-triazoles as novel oxazolidinone antibacterial agents with reduced activity against monoamine oxidase A. J Med Chem 2005;48:499-506.
129. Edmondson DE, Mattevi A, Binda C, Li M, Hubalek F. Structure and mechanism of monoamine oxidase. Curr Med Chem 2004;11:1983-93.
130. Binda C, Hubalek F, Li M, Edmondson DE, Mattevi A. Crystal structure of human monoamine oxidase B, a drug target enzyme monotopically inserted into the mitochondrial outer membrane. FEBS Lett 2004;564:225-8.
131. Binda C, Hubalek F, Li M, Herzig Y, Sterling J, Edmondson DE, et al. Crystal structures of monoamine oxidase B in complex with four inhibitors of the N-propargylaminoindan class. J Med Chem 2004;47:1767-74.
132. Binda C, Li M, Hubalek F, Restelli N, Edmondson DE, Mattevi A. Insights into the mode of inhibition of human mitochondrial monoamine oxidase B from high-resolution crystal structures. Proc Natl Acad Sci USA 2003;100:9750-5.
133. Cavalli A, Greco G, Novellino E, Recanatini M. Linking CoMFA and protein homology models of enzyme-inhibitor interactions: an application to nonsteroidal aromatase inhibitors. Bioorg Med Chem 2000;8:2771-80.
134. Sonnet P, Dallemagne P, Guillon J, Enguehard C, Stiebing S, Tanguy J, et al. New aromatase inhibitors, synthesis and biological activity of aryl-substituted pyrrolizine and indolizine derivatives. Bioorganic Med Chem 2000;8:945-55.
135. Laughton CA, Zvelebil MJ, Neidle S. A detailed molecular model for human aromatase. J Steroid Biochem Mol Biol 1993;44:399-407.
136. Lewis DF, Lee-Robichaud P. Molecular modelling of steroidogenic cytochromes P450 from families CYP11, CYP17, CYP19 and CYP21 based on the CYP102 crystal structure. J Steroid Biochem Mol Biol 1998;66:217-33.
137. Vanden Bossche H, Koymans L, Moereels H. P450 inhibitors of use in medical treatment: focus on mechanisms of action. Pharmacol Ther 1995;67:79-100.
138. Buchwald P. Structure-metabolism relationships: steric effects and the enzymatic hydrolysis of carboxylic esters. Mini Rev Med Chem 2001;1:101-11.
139. McElroy NR, Jurs PC, Morisseau C, Hammock BD. QSAR and classification of murine and human epoxide hydrolase inhibition by urea-like compounds. J Med Chem 2003;46:1066-80.
140. Kim EJ, Kim KS, Shin WH. Electrophysiological safety of DW-286a, a novel fluoroquinolone antibiotic agent. Hum Exp Toxicol 2005;24:19-25.
141. Lewis DF, Lake BG, Bird MG. Molecular modelling of human microsomal epoxide hydrolase (EH) by homology with a fungal (Aspergillus niger) EH crystal structure of 1.8 Å resolution: structure-activity relationships in epoxides inhibiting EH activity. Toxicol In Vitro 2005;19:517-22.
142. Gomez GA, Morisseau C, Hammock BD, Christianson DW. Structure of human epoxide hydrolase reveals mechanistic inferences on bifunctional catalysis in epoxide and phosphate ester hydrolysis. Biochemistry 2004;43:4716-23.
143. Sipila J, Hood AM, Coughtrie MW, Taskinen J. CoMFA modeling of enzyme kinetics: Km values for sulfation of diverse phenolic substrates by human catecholamine sulfotransferase SULT1A3. J Chem Inf Comput Sci 2003;43:1563-9.
144. Lee KA, Fuda H, Lee YC, Negishi M, Strott CA, Pedersen LC. Crystal structure of human cholesterol sulfotransferase (SULT2B1b) in the presence of pregnenolone and 3'-phosphoadenosine 5'-phosphate. Rationale for specificity differences between prototypical SULT2A1 and the SULT2BG1 isoforms. J Biol Chem 2003;278:44593-9.
145. Rehse PH, Zhou M, Lin SX. Crystal structure of human dehydroepiandrosterone sulphotransferase in complex with substrate. Biochem J 2002;364:165-71.
146. King RS, Sharma V, Pedersen LC, Kakuta Y, Negishi M, Duffel MW. Structurefunction modeling of the interactions of the N-alkyl-N-hydroxyanilines with rat hepatic aryl sulfotransferase IV. Chem Res Toxicol 2000;13:1251-8.
147. Bidwell LM, McManus ME, Gaedigk A, Kakuta Y, Negishi M, Pedersen L, et al. Crystal structure of human catecholamine sulfotransferase. J Mol Biol 1999;293:521-30.
148. Gu Y, Guo J, Pal A, Pan SS, Zimniak P, Singh SV, et al. Crystal structure of human glutathione S-transferase A3-3 and mechanistic implications for its high steroid isomerase activity. Biochemistry 2004;43:15673-9.
149. Le Trong I, Stenkamp RE, Ibarra C, Atkins WM, Adman ET. 1.3-Å resolution structure of human glutathione S-transferase with S-hexyl glutathione bound reveals possible extended ligandin binding site. Proteins 2002;48:618-27.
150. Oakley AJ, Lo Bello M, Battistoni A, Ricci G, Rossjohn J, Villar HO, et al. The structures of human glutathione transferase P1-1 in complex with glutathione and various inhibitors at high resolution. J Mol Biol 1997;274:84-100.
151. Oakley AJ, Lo Bello M, Mazzetti AP, Federici G, Parker MW. The glutathione conjugate of ethacrynic acid can bind to human pi class glutathione transferase P1-1 in two different modes. FEBS Lett 1997;419:32-6.
152. Ji X, Tordova M, O'Donnell R, Parsons JF, Hayden JB, Gilliland GL, et al. Structure and function of the xenobiotic substrate-binding site and location of a potential non-substrate-binding site in a class pi glutathione S-transferase. Biochemistry 1997;36:9690-702.